The report highlights a fundamental flaw in the process, given the states and territories can and do make budget-driven decisions to prevent the administration of CAR-T and gene therapies funded through the National Health Reform Agreement. …
Report highlights the need for change on NHRA-funded therapies
May 9, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
OncoSil Medical completes recruitment in TRIPP-FFX clinical trial
July 23, 2025 - - Australian Biotech -
Nyrada advances Xolatryp towards Phase 2a trial in cardioprotection
July 23, 2025 - - Australian Biotech -
Amplia Therapeutics announces $25 million placement and launches share purchase plan
July 23, 2025 - - Australian Biotech -
Percheron Therapeutics announces publication of new preclinical HMBD-002 data
July 23, 2025 - - Australian Biotech -
US leads the way on cell and gene therapy with new rapid access program
July 23, 2025 - - Latest News -
Neuraxpharm continues international expansion with launch of Australian affiliate
July 23, 2025 - - Latest News -
Companies secure certification as 'Great Places to Work'
July 23, 2025 - - Latest News